MarketPulse

clear cell renal cell carcinoma

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kura Oncology's Darlifarnib-Cabozantinib Combo Shows Promise in Resistant Kidney Cancer

Kura Oncology reports darlifarnib plus cabozantinib achieved 44% response rate in cabozantinib-pretreated renal cell carcinoma patients, potentially overcoming drug resistance.
KURAclinical trial dataobjective response rate
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Neomorph Raises $100M Series B to Accelerate Molecular Glue Degrader Pipeline

Neomorph closes $100M Series B led by Deerfield Management to advance NEO-811, its molecular glue degrader for kidney cancer, and expand its pipeline.
REGNclinical trialbiotechnology